Calithera Biosciences, Inc. (CALA) Analysts See $-0.24 EPS

February 15, 2018 - By Marguerite Chambers

 Calithera Biosciences, Inc. (CALA) Analysts See $ 0.24 EPS
Investors sentiment decreased to 1.22 in Q3 2017. Its down 2.03, from 3.25 in 2017Q2. It dropped, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported.
Pnc Fincl Gp holds 1,000 shares. International Gru owns 20,536 shares. 49,474 are owned by Clarivest Asset Mngmt Ltd Liability. Numeric Invsts Ltd has invested 0.02% in Calithera Biosciences, Inc. (NASDAQ:CALA). Franklin Resources holds 750,000 shares or 0.01% of its portfolio. Artal Sa invested in 0.05% or 175,000 shares. Jacobs Levy Equity Management holds 18,565 shares or 0.01% of its portfolio. Millennium Mngmt Limited Liability accumulated 482,136 shares or 0.01% of the stock. Moreover, Blackrock has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 2.10M shares. Fred Alger Mgmt has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 10,000 shares. Royal Comml Bank Of Canada holds 0% in Calithera Biosciences, Inc. (NASDAQ:CALA) or 3,159 shares. Aqr Capital Mgmt Ltd Liability Corporation stated it has 496,274 shares or 0.01% of all its holdings. Virtu Fincl Ltd Co invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Gam Ag accumulated 40,200 shares or 0.03% of the stock. Connor Clark Lunn Invest Mngmt Limited has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 11,620 shares.

Analysts expect Calithera Biosciences, Inc. (NASDAQ:CALA) to report $-0.24 EPS on March, 15.They anticipate $0.21 EPS change or 46.67 % from last quarter’s $-0.45 EPS. After having $-0.17 EPS previously, Calithera Biosciences, Inc.’s analysts see 41.18 % EPS growth. The stock decreased 1.41% or $0.1 during the last trading session, reaching $7. About 256,369 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 15, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. (NASDAQ:CALA) Ratings Coverage

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Calithera Biosciences had 9 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Tuesday, October 25 by Citigroup. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The firm has “Buy” rating given on Tuesday, March 28 by H.C. Wainwright. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) has “Buy” rating given on Thursday, January 5 by H.C. Wainwright. The firm earned “Buy” rating on Friday, July 24 by Citigroup. On Tuesday, January 24 the stock rating was upgraded by Citigroup to “Neutral”. The rating was maintained by H.C. Wainwright with “Buy” on Monday, June 12.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $248.34 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Another recent and important Calithera Biosciences, Inc. (NASDAQ:CALA) news was published by Streetinsider.com which published an article titled: “Form SC 13G/A Calithera Biosciences, Filed by: VIKING GLOBAL INVESTORS LP” on February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.